PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (May 2025)
28 slides from PetVivo's investor presentation, May 2025
Slide 1: Investor Presentation
Investor Presentation May 2025 PETV (OTCQB)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those
Slide 3: Company Highlights
Company Highlights Focus on estimated $11B companion animal veterinary care and product sales market Spryng®, with our OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechanics for the management of lameness and other joint-related afflictions including osteoa
Slide 4: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $11B Veterinary Care and Product Sales Market Osteoarthritis: Current solutions treat symptoms, but do a common affliction of the joints not manage the cause • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are • Affects approximately 34 million adult dogs and 1 approv
Slide 5: An Optimal OA Solution: Spryng with OsteoCushion Technology
An Optimal OA Solution: Spryng with OsteoCushion Technology • Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function - Similar components/function found in natural cartilage (i.e. collagen, elastin and hepa
Slide 6: Spryng with OsteoCushion Technology
Spryng with OsteoCushion Technology • Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms • Purified natural components self-assemble to form an insoluble, hydrated matrix - Protein source bovine tissues (i.e. collagen and elastin) from isolated h
Slide 7: Spryng Mechanism of Action
Spryng Mechanism of Action • An animal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain and further loss of cartilage • Spryng reinforces synovial membrane function, without ph
Slide 8: Spryng Canine Success: Buggy
Spryng Canine Success: Buggy CONDITION TREATMENT RESULTS 1 • 13-year-old mixed breed. • While under heavy sedation, • Responded well to the bilateral each of Buggy’s hips were Spryng hip injections, improving • Last 2 years mobility issues have injected with 1.0 ml of Spryng within a short period of
Slide 9: Spryng Equine Case Study: Fergie
Spryng Equine Case Study: Fergie HISTORY EXAM & DIAGNOSIS RESULTS1 • 16-year-old Saddlebred mare. • Choppy gait in her backend, • Mild improvement after one • Fergie shows as a Saddlebred intermittent left front week. monthly and ridden 5–6 days lameness ~1 year. • After one month, substantially per
Slide 10: Spryng Competitive Distinctions
Spryng Competitive Distinctions Spryng EQUINE • Outcomes address affliction/not just symptoms • Current treatments rely on biologic activity to treat symptoms; Spryng Spryng CANINE provides structural components to address affliction • Price/Cost advantage • Derived from all natural materials • Ease
Slide 11: 11 | © PetVivo Holdings, Inc.
1. 11 11 | © PetVivo Holdings, Inc.
Slide 12: Spryng Tolerance Studies
Spryng Tolerance Studies Canine Tolerance Feline Tolerance Purpose: Assess tolerance of Spryng administration in Purpose: Assess tolerance of Spryng administration in cats. dogs. Design: 10 healthy female cats received intra-articular Design: 20 healthy dogs received intra-articular injection inject
Slide 13: Spryng Clinical Studies
Spryng Clinical Studies Canine Hip OA Canine Stifle OA/CCL Disease Purpose: Study the effects of Collagen-Elastin Hydrogel Purpose: Evaluate benefit and tolerability of an intra-articular Microparticles (Spryng) on pain & function secondary to hip injection of a collagen-elastin biomaterial into the
Slide 14: New Spryng Clinical Trials
New Spryng Clinical Trials Underway or Recently Completed, Awaiting Publication Canine Study at Colorado Canine Study Canine Study State University Principal investigators: Principal investigators: Principal investigators: Felix Jamie Gaynor DVM, MS, DACVA, Sherman Canapp DVM, MS, Duerr, DVM, MS, Dr
Slide 15: The only FDA reviewed PRP product
No Centrifuge Required Freeze-dried, pooled, leukoreduced, RBC removed, allogeneic. Consistent Dosing Platelet Derived Growth Factor (PDGF-BB) measured in every batch Total platelet dose per vial equals 4 billion platelets. No Blood Draw Sterility, endotoxin and mycoplasma evaluated every time. Conv
Slide 16: What is Platelet-Rich Plasma (PRP)?
What is Platelet-Rich Plasma (PRP)? ● The most common regenerative therapy utilized in veterinary medicine. ● Concentrated preparation of platelets and plasma. ● First published use in the 1970’s as an intralesional and fracture repair product in horses and dogs. Benefits of PRP Many publications in
Slide 17: Common Uses of Platelet-Rich Plasma in Veterinary Medicine
Common Uses of Platelet-Rich Plasma in Veterinary Medicine In Conjunction with Stem Cell Therapy Wound Healing Post Surgical Healing Ophthalmic Uses Dental and Oral ● Corneal Ulceration Surgical Procedures ● Keratoconjunctivitis Sicca ● Descemetocele Musculoskeletal Disease/Injury ● Osteoarthritis ●
Slide 18: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities • Spryng product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 • Initial batch sizes of approx. 500 syringes; planning to increase to batches of 5,000+ syringes per month. • Current production facility annual capacity is approxi
Slide 19: Comprehensive IP Portfolio
Comprehensive IP Portfolio • 12 US Patents and 9 Foreign Patents • Broad Claim Language - “Comprising” Transitions • 6 Detailed Proprietary Trade Secrets • Our Patents & Trade Secrets Protect: • Protein & Carbohydrate Based Thermoplastics • Biomaterials of Many Compositions • Medical, Drug Delivery
Slide 20: Market Overview: Companion Animal/Veterinarian
Market Overview: Companion Animal/Veterinarian • US Pet Spend increased from $123.6B in 2021 to $138.0B in 2022 • Veterinary care and products is a leading growth driver - $11B in 2021 in US • 63% of US Households own a pet - 83.0M Dogs; 50.0M Cats • Approximately 7.2M horses in US* • Pet owners’ sp
Slide 21: Pet Product Pipeline (FDA clearance not required)
Pet Product Pipeline (FDA clearance not required) Product Commercial Particle Based Devices Species Safety Pilot Efficacy No. Launch VD-01 Osteoarthritis Canine (SpryngTM) Q3 2021 VD-02 Osteoarthritis Equine (SpryngTM) Q3 2021 VD-03 Digital Cushion Lameness Equine (Brand TDB) VD-04 Urinary Incontine
Slide 22: Distribution Services Agreements and Engagements: Cencora (MWI), Covetrus, Clipper and Vedco
Distribution Services Agreements and Engagements: Cencora (MWI), Covetrus, Clipper and Vedco Distribution Partners Wholesale Partners MWI – PetVivo Distribution Services Agreement Terms: Vedco – Wholesaler Engagement: • Non-exclusive distribution agreement with ongoing annual • Wholesaler relationsh
Slide 23: PetVivo Strategic Partners
PetVivo Strategic Partners: Digital Landia, LLC (“Agentic Pet”) and PiezoBioMembrane, Inc. (“PBM”) Agentic Pet (Artificial Intelligence) Relationship – Strategic Alliance Agreement: • PetVivo shall: i) invest in and sponsor the Agentics AI Framework for all PetVivo customers, ii) market the AI Frame
Slide 24: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience John Lai Garry Lowenthal John F. Dolan April Boyce Bryan S. Monninger CEO, President & Director CFO General Counsel VP of Sales & Marketing VP of Distribution and Corporate Relations Tom Yarbrough, DVM, Josh Wilh
Slide 25: Strong Board of Directors and Advisors
Strong Board of Directors and Advisors Michael Eldred Joseph Jasper Robert Rudelius Diane Levitan Robert Costantino Spencer Breithaupt John Lai Director Director Director Director Director Director Director & CEO Noble Ventures Associate Professor Long Island University College of Veterinary Medicin
Slide 26: Growth Drivers
Growth Drivers • Clinical Studies • Expand Sales Force and Distribution • Ethos (CCL Study) – 40 dogs injected; • Add regional sales managers results of cohort 1 presented at VOS; • Distributor/Wholesaler networks: Vetcove results of cohort 2 presented at ACVS (Dec. 2021), MWI DSA (June 2022), • Eth
Slide 27: PetVivo Highlights
PetVivo Highlights Focus on estimated $11B companion animal veterinary care and product sales market Spryng®, with our OsteoCushion® Technology, is a veterinary device that promotes the restoration of joint mechanics for the management of lameness and other joint-related afflictions including osteoa
Slide 28: John Lai
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 PetVivo.com To order, contact info1@petvivo.com or 844-PET-VIVO (844-738-8486) Spryng with OsteoCushion Technology is a veterinary medical device by PetVivo, Inc. Spryng is a trademark of PetVivo Holdings, Inc. This product is covered